Endothelial dysfunction and metabolic effects of nitric oxide in human

Abstract

Shortage of nitric oxide (NO) is believed to be a key factor in the development of endothelial dysfunction. Metabolic effects of NO were analyzed in subjects with multiple metabolic disorders (essential arterial hypertension, platelet hyperaggregability, and hypercholesterolemia). Effects of the NO-inducing β1-adrenoblocker nebivolol on the blood rheology and lipid profile were studied in pilots regularly exposed to factors of flying work contributing to the development of endotheliocyte dysfunction. The dynamics of spontaneous platelet aggregation in pilots with arterial hypertension suggested that nebivolol produced a statistically significant general effect on platelets, reducing their baseline activation by eliminating endothelial dysfunction. This NO-inducing drug has an antiatherosclerotic effect. Metabolic effects of NO are essential for normalizing endothelial functions because this messenger interacts with key reactions of the pathogenic cascade in the cardiovascular continuum.